RxDoctor Payments Data

Charles Nolen, MD

Family Medicine · Fayette, ALNPI 1346289105

Payments from drug & device makers

$4,751in general payments, 2019–2025

Across 280 payments — averaging $16.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • GSK$743
  • Novo Nordisk$566
  • Amgen$340
  • Johnson & Johnson$248
  • AbbVie$167
  • plus $2K from 22 others

What the payments were for

  • Food & beverage$4,65698%
  • Education$952%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,751 in reported general payments places this provider in the 80th percentile of 1,680 family medicine providers in Alabama.

See all family medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$221,330
Medicare patients
356
Services billed
7,683

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin307$230,819
Trelegy ElliptaFluticasone/Umeclidin/Vilanter175$148,253
EliquisApixaban176$133,788
OzempicSemaglutide109$106,422
JanuviaSitagliptin Phosphate100$76,549
TrulicityDulaglutide73$67,395
FarxigaDapagliflozin Propanediol73$47,285
Tresiba Flextouch U-200Insulin Degludec44$44,149
Tresiba Flextouch U-100Insulin Degludec33$27,039
Repatha SureclickEvolocumab46$24,783
Breztri AerosphereBudesonide/Glycopyr/Formoterol27$24,175
EntrestoSacubitril/Valsartan12$22,271
Celecoxib494$19,855
XareltoRivaroxaban13$14,801
MyrbetriqMirabegron27$14,474

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$135$230,819307 claims
GSKTrelegy Ellipta$743$148,253175 claims
PfizerEliquis$81$133,788176 claims
Novo NordiskOzempic$566$106,422109 claims
MerckJanuvia$154$76,549100 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$1,163$75,695113 claims
Lilly USA, LLCTrulicity$148$67,39573 claims
NovartisEntresto$166$22,27112 claims
Johnson & JohnsonXarelto$248$14,80113 claims
Astellas Pharma US IncMyrbetriq$12$14,47427 claims
AbbVieLinzess$167$12,76623 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,680 family medicine providers in Alabama.

Other family medicine in Fayette

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →